FDA to release biosimilars plan July 18

FDA’s Biosimilars Action Plan is likely to include elements the agency has disclosed in recent months that are intended to make reviews of biosimilars more predictable, reduce barriers to gaining approval of interchangeable biologics, and remove barriers to biosimilar competition.

The

Read the full 413 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE